Rheumatoid arthritis (RA) is a debilitating
autoimmune disease characterized by chronic
inflammation of the synovial joints.
Collagen-induced arthritis (CIA) and
proteoglycan-induced
arthritis (PGIA) are mouse models of inflammatory
arthritis; CIA is a T helper type 17 (Th17) -dependent disease that is induced with
antigen in complete
Freund's adjuvant, whereas PGIA is Th1-mediated and is induced using
antigen in dimethyldioctadecyl-
ammonium bromide (
DDA) as an adjuvant. To investigate whether the type of adjuvant determines the
cytokine profile of the pathogenic T cells, we have compared the effect of CFA and
DDA on T-cell responses in a single
arthritis model. No differences in incidence or disease severity between
aggrecan-
T-cell receptor transgenic mice immunized with
aggrecan in either CFA or
DDA were observed. Immunization with CFA resulted in a higher proportion of Th17 cells, whereas
DDA induced more Th1 cells. However, the levels of
interleukin-17 (IL-17) produced by T cells isolated from CFA-immunized mice after
antigen-specific stimulation were not significantly different from those found in
DDA-immunized mice, indicating that the increased proportion of Th17 cells did not result in significantly higher ex vivo
IL-17 levels. Hence, the choice of adjuvant can affect the overall proportions of Th1 and Th17 cells, without necessarily affecting the level of
cytokine production or disease incidence and severity.